In this review
Use the plan totals before the teaser
The current cards list compounded semaglutide at $128 billed monthly or $359 every three months. Tirzepatide is $228 monthly or $597 every three months. The semaglutide card’s $119 monthly presentation is rounded; use the actual $359 charge. A separate $99 starting teaser elsewhere on the page does not establish a selected invoice. [1]
The refund policy adds a nonrefundable 4% processing fee. The complete quote should identify the supplied formulation, quantity, charge and renewal date. The listed plan includes provider review, medicine, supplies and expedited delivery; do not import the NAD+ first-order discount into this separate GLP-1 price. [1] [2]
Compare selected invoices and renewal periods in the full GLP-1 cost planner.
Included education has a defined format
Lose It for Life is a self-paced digital course with videos, guides and exercises. The GLP-1 page also lists its nutrition programme, provider messaging and concierge calls or texts. These are specific features to compare, but they do not establish recurring one-to-one dietitian or psychotherapy appointments. [1] [3]
The dedicated course page says lifetime access, while the general FAQ limits education and community access to active therapy enrollment. Confirm which access survives cancellation. The course’s behavior-change story does not prove it prevents weight regain after stopping treatment. [3] [4]
For a different scheduled-care model, compare our Form Health continuing-care review.
The guarantee requires no measurable weight loss
The policy’s eligible-program guarantee requires 180 consecutive days, timestamped starting and monthly weights, a final weight and the same scale. Any measurable weight loss voids eligibility. The claim must arrive within fourteen days of completion and remains subject to compliance and documentation review. It is not a refund for losing less than hoped. [2]
It concerns eligible medication fees, not a promise to return every payment; the $35 visit fee is excluded and processing is separately described as nonrefundable. Ordinary cancellation also has a twelve-hour email window and earlier processing/finality clauses. Resolve the actual applicable order terms before paying. [2]
Read a different conditional remedy in our HelloWellness refund-and-transfer review.
For another prescription service with a different supply and payment description, read our LaSara plan-and-supply review.
The supplied prescription still needs its own justification
Terms assign the pharmacy according to clinical and operational factors and leave the prescribing decision with the clinician. FAQ nationwide GLP-1 access remains qualified by medical eligibility and state rules. No intake guarantees a prescription, and a pharmacy-standard logo does not establish an actual batch’s result. [4] [5]
Compounded drugs are not FDA-approved generic equivalents; current FDA rules retain patient-specific conditions after shortage resolution. Compare the actual care and preparation rather than borrow branded-trial results or treat a course and guarantee as evidence that the medicine works better. [6] [7]
Keep function and lean mass beside scale change with the GLP-1 body-composition evidence.
Understanding the cost
Semaglutide $128/month or $359 per quarter; tirzepatide $228/month or $597 per quarter. Quarterly monthly equivalents are not installment prices. Separate $99 teaser is not a complete quote. Confirm selected invoice, 4% processing fee, actual prescription and renewal.
Build your cost estimateSources
- Telezen MD: compounded GLP-1 monthly and quarterly cards and included care
- Telezen MD: cancellation, fees, shipment claims and conditional weight-loss guarantee
- Telezen MD: self-paced course, lifetime-access claim and educational limits
- Telezen MD: expanded laboratory, state, route, cancellation and access FAQs
- Telezen MD: independent providers, assigned pharmacy and clinical eligibility
- FDA: compounded drugs and premarket approval limits
- FDA: patient-specific GLP-1 compounding conditions after shortage resolution
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.